Lurosetron

Lurosetron

SCHEMBL788289

Cc1[nH]cnc1CN1CCc2c(c3cccc(F)c3n2C)C1=O

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.72
CYP1A2 P05177 1/20 0.72
CYP3A4 P08684 1/20 0.72
ADRA2C P18825 1/20 0.72
HTR2A P28223 1/20 0.72
HTR2C P28335 1/20 0.72
ADRA1A P35348 1/20 0.72
HTR2B P41595 1/20 0.72
HTR3A P46098 1/20 0.72
CASP6 P55212 1/20 0.71
CD44 P16070 2/20 0.38
P2RX7 Q99572 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lurosetron SCHEMBL30949356 1.00 KCNH2 (0.72) KCNH2CYP1A2CYP3A4ADRA2CHTR2A
Lurosetron SCHEMBL7291773 0.99 CASP6 (0.72) KCNH2CYP1A2CYP3A4ADRA2CHTR2A
Lurosetron SCHEMBL7336906 0.99 KCNH2 (0.71) KCNH2CYP1A2CYP3A4ADRA2CHTR2A
Lurosetron SCHEMBL635328 0.95 KCNH2 (0.66) KCNH2CYP1A2CYP3A4ADRA2CHTR2A
Lurosetron SCHEMBL7336554 0.95 KCNH2 (0.65) KCNH2CYP1A2CYP3A4ADRA2CHTR2A
Lurosetron SCHEMBL7282816 0.93 KCNH2 (0.63) KCNH2CYP1A2CYP3A4ADRA2CHTR2A
Lurosetron SCHEMBL9486016 0.93 KCNH2 (0.63) KCNH2CYP1A2CYP3A4ADRA2CHTR2A
Lurosetron SCHEMBL7284073 0.92 KCNH2 (0.65) KCNH2CYP1A2CYP3A4ADRA2CHTR2A
SCHEMBL7285588 0.90 KCNH2 (0.74) KCNH2CYP1A2CYP3A4ADRA2CHTR2A
SCHEMBL7293493 0.88 KCNH2 (0.72) KCNH2CYP1A2CYP3A4ADRA2CHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11547700-B2 Compositions and methods for treating synucleinopathies CHASE THERAPEUTICS CORPORATION (US) 2023-01-10 US claimed
WO-2016118540-A1 TREATING AND/OR PREVENTING EMESIS AND/OR NAUSEA INCLUDING ACUTE AND/OR DELAYED NAUSEA AND/OR EMESIS Xoc Pharmaceuticals, Inc. (US) 2016-07-28 WO claimed
US-20160206610-A1 METHODS FOR TREATING AND/OR PREVENTING EMESIS AND/OR NAUSEA INCLUDING ACUTE AND/OR DELAYED NAUSEA AND/OR ACUTE EMESIS AND/OR DELAYED EMESIS Xoc Pharmaceuticals, Inc. 2016-07-21 US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
CN-103402513-A Composition for preventing nausea or vomiting SAMYANG BIOPHARMACEUTICALS 2013-11-20 CN claimed
EP-2658539-A2 COMPOSITION FOR PREVENTION OF NAUSEA OR VOMITING Samyang Biopharmaceuticals Corporation (KR) 2013-11-06 EP claimed
US-20130267487-A1 COMPOSITION FOR PREVENTION OF NAUSEA OR VOMITING SAMYANG BIOPHARMACEUTICALS CORPORATION (KR) 2013-10-10 US claimed
WO-2012091357-A2 COMPOSITION FOR PREVENTION OF NAUSEA OR VOMITING SAMYANG BIOPHARMACEUTICALS CORPORATION (KR) 2012-07-05 WO claimed
CN-1925846-B Use of a 5-HT3 receptor antagonist for the manufacture of a medicament for the treatment of non-digestive tract derived abdominal disorders associated with pain SOLVAY PHARM BV 2011-11-16 CN claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
US-6235745-B1 ADMINISTERING WITH LAXATIVE JANSSEN PHARMACEUTICA N.V. (BE) 2001-05-22 US claimed
EP-0975327-A1 USE OF 5HT3 ANTAGONISTS FOR PROMOTING INTESTINAL LAVAGE JANSSEN PHARMACEUTICA N.V. (BE) 2000-02-02 EP claimed
WO-1998047481-A1 USE OF 5HT3 ANTAGONISTS FOR PROMOTING INTESTINAL LAVAGE JANSSEN PHARMACEUTICA N.V. (BE) 1998-10-29 WO claimed
EP-0546593-B1 Multi-layered compositions containing histamine or serotonin antagonists GLAXO GROUP LTD (GB) 1997-09-03 EP claimed
EP-0353983-B1 Lactam derivatives GLAXO GROUP LTD (GB) 1996-05-29 EP claimed
EP-0542364-B1 Controlled release device GLAXO CANADA (CA) 1996-01-24 EP claimed
US-5425950-A Antiserotonine agent GLAXO GROUP LIMITED (GB) 1995-06-20 US claimed
EP-0546593-A1 Multi-layered compositions containing histamine or serotonin antagonists GLAXO GROUP LIMITED (GB) 1993-06-16 EP claimed
US-5183820-A Useful for treatment of nausea, vomiting, irritable bowel syndrome and dyspepsia GLAXO GROUP LIMITED (GB) 1993-02-02 US claimed
EP-0353983-A2 Lactam derivatives GLAXO GROUP LIMITED (GB) 1990-02-07 EP claimed